Sponsors
Alkermes is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. Headquartered in Dublin, Ireland, Alkermes has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of candidates in development for neurological disorders.
Bioprojet was established in order to bring academic research closer to industrial pharmaceutical development, a practice that was not very widespread 1982. We have one objective: to apply ourselves to original work in basic research in order to design and develop drugs which are the first of their kind in new therapeutic classes.
Bioprojet is comprised of Bioprojet PHARMA, responsible for the development and marketing of medicines and Bioprojet BIOTECH which oversees all of the group’s R&D. Today we provide pharmaceutical research in neurology, gastro-enterology, allergology, oncology & cardio-pneumology.
Idorsia is reaching out for more – We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core.
Nox Medical is a global leader in the sleep diagnostic technology space. We provide sleep specialists with patient-friendly diagnostic devices and robust, reliable data collection.
With easy-to-use medical device technology, Nox Medical eliminates common diagnostic pain points by prioritizing patient comfort and reliability of results, allowing providers to better assess, diagnose and treat the entire range of sleep health issues, including sleep apnea, circadian disorders and insomnia.
Key product lines include Nox A1s PSG system, Nox T3s home sleep test, Nox SAS solution, and Noxturnal single platform software.
Pharmanovia is a global lifecycle management healthcare company. Our purpose is to make medicines fit for tomorrow, to improve the lives of patients globally.
We do this by commercializing novel medicines and technologies as well as rediscovering, repurposing or re-engineering established medicines to improve patient outcomes and experiences.
With a diverse and growing team in over 160 countries across the globe, we deliver high-quality solutions, ethically and sustainably, across our four core therapeutic areas – Neurology, Endocrinology, Cardiovascular and Oncology.
Takeda Neuroscience is driven by the unmet needs of patients with rare neurological diseases. Our mission is to bring innovative and potentially disease-modifying medicines to these patients.
To deliver on this mission, our approach leverages advances in molecularly and genetically defined targets, biomarkers, and targeted modalities. Our commitment to patients is focused on our goal of developing new treatments for those who need them most.
Philips is a health technology company focused on improving people’s health and well-being through meaningful innovation – from healthy living and prevention to diagnosis, treatment and home care.
Applying advanced technologies and deep clinical and consumer insights, Philips partners with customers to deliver integrated solutions that help provide improved patient experience, better health outcomes, improved staff experience, and lower cost of care.
At ResMed, we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases.
Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries.
SOMNOmedics designs, manufactures, markets, distributes and services products dedicated to sleep diagnostics. Our products are utilized for a variety of sleep related tests and comply with the AASM standards. SOMNOmedics devices are small, lightweight and worn by the patient. We are compatible with in lab diagnostics as well as home sleep testing.
SOMNOmedics wireless solution allows patients video, audio and data to be observed from any environment.
VIVISOL, a company part of SOL Group, has been active for over 35 years in homecare services. VIVISOL services cover many therapeutic areas, including respiratory care, nursing, infusion therapies, advanced homecare, home dialysis, and assistive devices development, production, and distribution.
As a world leader in healthcare services, Air Liquide Healthcare supports 2 million people at home, who mainly live with chronic respiratory diseases like COPD, sleep apnea and respiratory failure. Our patient-centered approach is based on the principles of Value-based Healthcare.
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options.
Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy.
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients. Our most advanced programs include a hemophilia program, an orexin agonist program for the treatment of narcolepsy and other sleep-wake disorders, and an immuno-oncology program focused on our LockBody® technology platform.
We operate with the conviction that each of our programs has the potential to change the current treatment paradigm and establish a new standard of care. For more information, visit www.centessa.com.
NLS Pharmaceutics is a Swiss clinical-stage biopharmaceutical company led by an experienced management team with a track record of developing and repurposing product candidates to treat rare and complex CNS disorders. We have recently completed a phase 2 study in the US in adult subjects with narcolepsy with its lead asset, a proprietary extended-release formulation of mazindol (mazindol ER). Mazindol is a triple monoamine reuptake inhibitor and partial orexin-2 receptor agonist.